RFK vaccine inquiry: process risk

The 2025/06/18 headline matters because it moves the RFK Jr. vaccine story from rhetoric to process risk inside HHS nytimes.com. The market split is between a diffuse inquiry and any formal review that may begin to touch recommendations, approvals, or purchasing.

The 2025/06/18 headline is the news: the New York Times says RFK Jr. is driving a broad vaccine inquiry inside HHS despite staying publicly quiet, which shifts the story from rhetoric to process risk nytimes.com. Public detail is still thin, so the market frame is simple. For vaccine names, the beat scenario would likely be a diffuse information-gathering exercise with no change to recommendations, labels, approvals, or federal purchasing. The miss scenario could be any documentary step that formalizes review or procurement, because that expands the range of eventual policy outcomes before any rule change arrives. That is why the first market effect could manifest as multiple compression rather than a clean earnings reset. The only clear primary data point in the accessible record here is the vaccine and toxoid producer-price index, which was 261.878 on 2025-01-01 and 264.126 on 2025-07-01, suggesting the sector backdrop was not obviously soft going in fred.stlouisfed.org. What would change the reaction is evidence that the inquiry may begin to alter recommendations, approvals, or purchasing.